Abstract:Background: Stroke is a common neurological disorder that disproportionately affects middle-aged and elderly individuals, leading to significant disability and mortality. Recently, human blood metabolites have been discovered to be useful in unraveling the underlying biological mechanisms of neurological disorders. Therefore, we aimed to evaluate the causal relationship between human blood metabolites and susceptibility to stroke. Methods: Summary data from genome-wide association studies (GWASs) of serum metabolites and stroke and its subtypes were obtained separately. A total of 486 serum metabolites were used as the exposure. Simultaneously, 11 different stroke phenotypes were set as the outcomes, including any stroke (AS), any ischemic stroke (AIS), large artery stroke (LAS), cardioembolic stroke (CES), small vessel stroke (SVS), lacunar stroke (LS), white matter hyperintensities (WMH), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), transient ischemic attack (TIA), and brain microbleeds (BMB). A two-sample Mendelian randomization (MR) study was conducted to investigate the causal effects of serum metabolites on stroke and its subtypes. The inverse variance-weighted MR analyses were conducted as causal estimates, accompanied by a series of sensitivity analyses to evaluate the robustness of the results. Furthermore, a reverse MR analysis was conducted to assess the potential for reverse causation. Additionally, metabolic pathway analysis was performed using the web-based MetOrigin. Results: After correcting for the false discovery rate (FDR), MR analysis results revealed remarkable causative associations with 25 metabolites. Further sensitivity analyses confirmed that only four causative associations involving three specific metabolites passed all sensitivity tests, namely ADpSGEGDFXAEGGGVR* for AS (OR: 1.599, 95% CI 1.283-1.993, p = 2.92 × 10-5) and AIS (OR: 1.776, 95% CI 1.380-2.285, p = 8.05 × 10-6), 1-linoleoylglycerophosph-oethanolamine* for LAS (OR: 0.198, 95% CI 0.091-0.428, p = 3.92 × 10-5), and gamma-glutamylmethionine* for SAH (OR: 3.251, 95% CI 1.876-5.635, p = 2.66 × 10-5), thereby demonstrating a high degree of stability. Moreover, eight causative associations involving seven other metabolites passed both sensitivity tests and were considered robust. The association result of one metabolite (glutamate for LAS) was considered non-robust. As for the remaining metabolites, we speculate that they may potentially possess underlying causal relationships. Notably, no common metabolites emerged from the reverse MR analysis. Moreover, after FDR correction, metabolic pathway analysis identified 40 significant pathways across 11 stroke phenotypes. Conclusions: The identified metabolites and their associated metabolic pathways are promising circulating metabolic biomarkers, holding potential for their application in stroke screening and preventive strategies within clinical settings.

Causal associations of fatigue and functional outcome after ischemic stroke: a mediation Mendelian randomization study

Immune Cells and Blood Lipids Mediation: a Mendelian Randomization Study on Metabolic Dysfunction-Associated Fatty Liver Disease

Genetically Predicted Sleep Traits and Functional Outcome After Ischemic Stroke: A Mendelian Randomization Study

Causal association between self-reported fatigue and coronary artery disease: a bidirectional two-sample Mendelian randomization analysis

Association of Genetically Predicted Anxiety and Depression with Functional Outcome after Ischemic Stroke

The Association of Arterial Stiffness Index with Cerebrovascular and Cardiometabolic Disease: A Mendelian Randomization Study

Genetic liability to frailty in relation to functional outcome after ischemic stroke

Genetic causality of lipidomic and immune cell profiles in ischemic stroke

The Association Between Fatigue and Cardiometabolic Diseases: Insights from the UK Biobank Study

Causal effects of immune cell surface antigens and functional outcome after ischemic stroke: a Mendelian randomization study

Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke

Early poststroke clinically significant fatigue predicts functional independence: a prospective longitudinal study

Diet-derived circulating antioxidants and functional outcome after ischemic stroke: Evidence from genetic studies

Heart Failure and Ischemic Stroke: A Bidirectional and Multivariable Mendelian Randomization Study

Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study

Association Between Blood Pressure and Different Antihypertensive Drugs with Outcome after Ischemic Stroke: A Mendelian Randomization Study.

Genetically Predicted Smoking and Alcohol Consumption and Functional Outcome After Ischemic Stroke

Systematic Druggable Genome‐Wide Mendelian Randomization Identifies Therapeutic Targets for Functional Outcome after Ischemic Stroke

Genetically Determined Sex Hormones and Functional Outcome after Ischemic Stroke: A Mendelian Randomization Study

Causal relationship between metabolites and embolic stroke: based on Mendelian randomization and metabolomics

Non-alcoholic fatty liver disease and stroke: A Mendelian randomization study